에 대한 최신 뉴스 Kenvue (NYSE:KVUE) 주식

Kenvue

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Display,Of,Stock,Market,Quotes,With,City,Scene,Reflect,On

Equities

News

Markets

AVGO

KVUE

MRVL

NVDA

QRVO

RIOT

SWKS

행동주의 투자자 스타보드 밸류 LP는 목요일(16일) 코보(NASDAQ:QRVO)의 지분 7.7%를 인수한 것응로 알려졌다. 운영 변경을 위한 잠재적인 타깃으로 부진한 반도체 제조업체를 겨냥한 것이다.

코보, 행동주의 투자자 스타보드의 지분 취득 소식 이후 시간외 거래 7%↑

What He Said

행동주의 투자자인 스타보드 밸류(Starboard Value)는 타이레놀(Tylenol) 및 리스테린(Listerine)과 같은 인기 소비자 제품을 생산하는 회사인 켄뷰(NYSE:KVUE)의 상당한 지분을 인수한 것으로 알려졌다.

타이레놀과 리스테린 제조업체 켄뷰는 스타보드 밸류의 지분 투자로 행동주의 투자자들이 주목

S&P 500 Earnings

ABNB

ACGL

AXON

BBWI

CRWD

DLTR

ETSY

FTNT

GDDY

INTC

MPWR

MRNA

SBUX

SMCI

UBER

8월에는 주식 시장이 7월 중순 정점 이후 겪은 손실을 만회했으며, 이는 실적과 양호한 데이터가 반등에 도움이 되었다. 8월을 뒤로 보내면서 시장 성과를 더욱 폭넓게 측정하는 S&amp;P 500 지수의 상승주와 하락주를 살펴보겠다.

8월 S&amp;P 500의 상위 상승주와 하락주: 매그 7종목은 빠지고, 사이버 보안 2종목 포함

Kenvue Inc

Major Wall Street investment banks are divided over how the dollar will move from here, yet much clarity could be just days away as a deluge of <a href="https://www.benzinga.com/news/econ-s">key economic data looms.</a>
In an outlook shared with clients last week, Wells Fargo's economics team, led by Nick Bennenbroek, expressed a bullish short-term stance on the U.S. dollar, calling the recent wave of depreciation &#8220;tactical&#8221; rather than the beginning of a structural trend.
"We expect the U.S. dollar to rebound in the immediate period ahead," the analysts said, suggesting the dollar will remain fundamentally supported before resuming trend strength into 2026.
<h3 class="wp-block-heading">Bearish Positioning Builds As Speculators Eye US Economic Weakness</h3>
 Speculative net short positions against the greenback — measured across 10 major currencies and the Dollar Index (DXY) — surged to $40 billion last week, the highest level since October 2023, according to Commodity Futures Trading Commission data.
The Dollar Index, as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), has dropped 8% year-to-date, reaching its most oversold levels since December 2020 last week.
Technically, it is now 5.5% below its 200-day and 4.5% below its 50-day moving averages, underscoring how aggressive the recent selloff has been.
Wells Fargo indicated that unusual dynamics are pressuring the dollar, particularly the political noise and tariff volatility emanating from the U.S. 
"With the source of policy uncertainty and volatility coming out of the United States, market participants have sold dollar-denominated assets and moved away from Treasuries," they said. 
Yet, the team described this as &#8220;a transitory phenomenon,&#8221; not a fundamental reassessment of U.S. assets.
<h3 class="wp-block-heading">Goldman Sachs Sees Further Dollar Weakness Ahead</h3>
Over at Goldman Sachs, foreign exchange analyst Kamakshya Trivedi took the opposite side of the trade.
"Even after a swift move in recent weeks, we believe that the dollar has further to fall," Trivedi said. 
The investment bank highlights that the underperformance of U.S. assets and the reduction in global investors' enthusiasm for unhedged dollar assets could trigger a longer-lasting decline in the greenback.
Trivedi emphasized that investors may be overestimating the impact of short-term positioning while underestimating the structural reallocation already underway. 
"We are more focused on the likely shift in future allocations," he said, citing historical parallels where changes in investor appetite led to persistent exchange rate moves.
Goldman's concern is compounded by ongoing uncertainty around U.S. trade and monetary policy. 
While President Donald Trump's recent statements hint at potential tariff rollbacks and efforts to reassure markets — including backing off pressure on the Fed — the bank is unconvinced these efforts will quickly restore investor confidence.
<h3 class="wp-block-heading">Dollar Direction Hinges On Upcoming Macro Data</h3>
The next few trading days could be decisive for the dollar&#8217;s short-term fate, with several high-impact U.S. economic reports on deck:
<ul>
<li>Q1 2025 GDP (Wednesday): Expected to slow sharply from 2.8% in Q4 2024 to 0.4%, according to median economist consensus tracked by TradingEconomics.</li>
<li>Personal Consumption Expenditure (PCE) price index (Wednesday): Fed's preferred inflation gauge expected to cool to from 2.5% to 2.2% in March, with core PCE dropping from 2.8% to 2.6%</li>
<li>April Jobs Report (Friday): Forecasts see nonfarm payrolls at 135,000, down from 228,000, with unemployment steady at 4.2%</li>
</ul>
If the data confirm a softening U.S. economy, it could validate Goldman Sachs' bearish thesis, especially as investors price in earlier and deeper Federal Reserve rate cuts. 
On the flip side, any surprise economic resilience in jobs or inflation could lend weight to Wells Fargo's tactical dollar rebound call.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Currency ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

Dollar Under Pressure: Wall Street Split Widens Ahead Of High-Stakes US Data

Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) has seen its stock climb 50% to $1.34 over the past week following a series of company announcements.
What To Know: The California-based electric vehicle maker recently <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">appointed</a> founder YT Jia as Co-CEO alongside current CEO Matthias Aydt, signaling a new dual-leadership structure. Jia will oversee finance, legal and supply chain operations in addition to his current responsibilities. His new equity incentive package is tied to market cap and stock performance.
At the company's recent "FF Stockholder Community and FX Co-Creation Day" in Los Angeles, Jia outlined strategic goals including launching the first FX model by end of 2025, achieving positive gross margin and operating cash flow and pursuing global AI and AIEV M&amp;A initiatives. 
California <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">political figures</a> including former Assembly Speaker Anthony Rendon and Hanford Mayor Lou Martinez expressed public support for the company's transformation efforts. 
Faraday Future emphasized its intent to maximize stakeholder value and resist illegal short-selling as it executes its Global Bridge Strategy.
Read Also: <a href="https://www.benzinga.com/news/25/04/45078865/d-wave-quantum-qbts-stock-falls-amid-valuation-critique-by-kerrisdale-capital">D-Wave Quantum Stock Falls Amid Valuation Critique By Kerrisdale Capital</a>
<h2 class="wp-block-heading">How To Buy FFAI Stock</h2>
By now you're likely curious about how to participate in the market for Faraday Future &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Faraday Future, which is trading at $1.33 as of publishing time, $100 would buy you 75.19 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, FFAI has a 52-week high of and a 52-week low of

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Faraday Future (FFAI) Shares Surge 50% Amid Leadership Changes And Strategic Updates

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2F&amp;esheet=54246103&amp;newsitemid=20250429590949&amp;lan=en-US&amp;anchor=BeiGene&amp;index=1&amp;md5=0c09798a0c67c852789b965c290809ae">BeiGene</a>, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.
On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA&#xAE; (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene's petition to institute the PGR. The USPTO's Final Written Decision is appealable by Pharmacyclics.
Commenting on the ruling, BeiGene General Counsel Chan Lee said: "We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today's decision reinforces our belief that Pharmacyclics' ‘803 patent is overly broad and invalid. BeiGene is confident in the strength of our intellectual property supporting BRUKINSA, a clearly differentiated and independently developed medicine. With approvals in more than 70 countries and regions for the treatment of multiple B-cell malignancies, BRUKINSA continues to set a new standard of care for patients worldwide."

USPTO Renders Final Decision, Invalidating All Challenged Pharmacyclics Patent Claims Against BeiGene

SoFi Technologies Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) stock price gained Tuesday after it reported its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45062395/sofi-reports-first-quarter-2025-with-record-net-revenue-of-772-million-record-member-and-product-g" rel="noreferrer noopener">first-quarter 2025</a> earnings on Tuesday. Here's a look at the&nbsp;key metrics from the quarter.
The company reported quarterly adjusted sales of $770.72 million, beating analyst estimates of $739.04 million. The company reported quarterly adjusted earnings of 6 cents per share, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating&nbsp;analyst estimates of</a> 4 cents per share.
Adjusted revenue rose 33% year-over-year. Financial services revenue increased by 101% year-over-year, lending segment revenue increased by 25% year-over-year, and technology platform revenue increased by 10% year-over-year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44989977/sofi-stock-is-up-11-this-week-whats-going-on" rel="noreferrer noopener">SoFi Stock Jumps as It Opens AI and Private Market Investments to Everyday Investors</a>
Net interest income of&nbsp;$498.7 million&nbsp;was up 24%&nbsp;year-over-year, driven by a&nbsp;23%&nbsp;growth in average interest-earning assets and an 82 basis points decrease in cost of funds.
SoFi added 800,000 new members in the quarter, bringing total members up to 10.9 million, up 34% year-over-year. Product additions totaled nearly 1.2 million in the quarter.
SoFi&nbsp;CEO&nbsp;Anthony Noto&nbsp;<a target="_blank" href="https://www.cnbc.com/2025/04/29/sofi-crypto-investing.html" rel="noreferrer noopener">told</a> CNBC in an interview Tuesday that the fintech bank will bring back cryptocurrency investing this year following a shift in the regulatory landscape under the Trump administration. It had to dump crypto investing in late 2023 to bag a bank charter.&nbsp;
Outlook: In the second quarter of 2025, SoFi expects to generate $785 million—$805 million of adjusted net revenue versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimates of</a> $783.02 million, $200 million—$210 million of adjusted EBITDA, $60 million—$70 million of GAAP net income and $0.05-$0.06 of GAAP EPS (below the estimate of $0.06).
For the full year 2025, the company expects adjusted net revenue of $3.235 billion-$3.310 billion (<a href="https://www.benzinga.com/25/01/43233747/sofi-q4-earnings-24-revenue-increase-adds-785k-members-ceo-highlights-strong-financial-services-momentum-projects-23-26-revenue-growth-for-2025" target="_blank" rel="noreferrer noopener">prior $3.200 billion-$3.275 billion</a>) versus analyst consensus of $3.200 billion, which equates to approximately 24%-27% (prior 23%-26%) year-over-year growth.
Sofi anticipates an adjusted EBITDA of $875 million-$895 million (prior $845 million-$865 million), GAAP net income of $320 million- $330 million (prior $285 million-$305 million), and GAAP EPS of $0.27-$0.28 (prior $0.25 to $0.27) versus consensus of $0.26. 
Price Action: SOFI stock is up 2.84% at $13.58 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526669/jim-cramer-says-dont-buy-this-financial-stock-at-this-level-let-it-come-in" target="_blank" rel="noreferrer noopener">Cramer Cautions on SoFi Stock After Weak 2025 Profit Outlook</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Fintech news covering the emerging Financial Technology services sector

Fintech

Guidance

Movers

Tech

SOFI

SoFi Stock Pops As Revenue Soars And CEO Teases Crypto Comeback

Vacasa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) ("Vacasa" or the "Company"), a leading vacation rental management platform in North America, today announced that its stockholders have approved the proposed merger with Casago (the "Merger").
On April 29, 2025, Vacasa held a special meeting of the Company's stockholders (the "Special Meeting") to vote on a proposal (the "Merger Agreement Proposal") to adopt the Agreement and Plan of Merger, dated as of December 30, 2024, as amended by Amendment No. 1 thereto, dated as of March 17, 2025, and by Amendment No. 2 thereto, dated as of March 28, 2025. At the Special Meeting, approximately 69% of the Company's Class A common stock, 96% of the Company's Class B common stock and 72% of the Company's Class A common stock and Class B common stock, voting together as a single class, voted in favor of the Merger Agreement Proposal.
The Company expects closing of the Merger to occur at 11:59 pm ET on April 30, 2025, subject to the satisfaction or waiver of the remaining closing conditions.

VCSA

Vacasa Stockholders Approve Proposed Merger With Casago

Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares fell 13.2% to $12.85 during Tuesday&#8217;s session after the solar-grade polysilicon producer reported <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">worse-than-expected</a> first-quarter results, signaling possible industry struggles.
What To Know: The company posted an adjusted net loss of 80 cents per ADS, wider than analyst expectations of a 69 cent loss. Revenue dropped 70% year-over-year to $123.9 million, missing the $182.1 million consensus. The sharp decline was driven by lower sales volumes and weak pricing, amid persistent overcapacity and muted demand in the solar PV market.
Gross margin plunged to -65.8% from +17.4% a year ago, with a gross loss of $81.5 million. Polysilicon average selling prices dropped to $4.37/kg, below both production and cash costs. Despite losses, Daqo&#8217;s balance sheet shows $2.15 billion in liquid assets and <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">no financial debt</a>.
CEO Xiang Xu said the company ran at 33% capacity to manage inventory and mitigate low prices. Looking ahead, Daqo expects second-quarter polysilicon output of 25,000–28,000 MT. Management remains confident in long-term prospects, citing cost leadership, new technologies and China&#8217;s push for solar expansion.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/45073201/plug-power-stock-is-trending-tuesday-whats-going-on">Plug Power Stock Is Trending Tuesday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy DQ Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Daqo New Energy&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DQ has a 52-week high of $30.85 and a 52-week low of $12.40.

Daqo New Energy (DQ) Stock Slides On Steep Revenue, Earnings Miss In Q1

Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) reported first-quarter financial results before the market open on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/n45062385/the-sherwin-williams-company-reports-2025-first-quarter-financial-results">from the quarter</a>.
<ul>
<li>Q1 Revenue: $5.31 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $5.4 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $2.25, versus estimates of $2.16 per share</li>
</ul>
Sherwin-Williams said total sales declined 1.1% year-over-year. Consumer Brands Group sales fell 6% year-over-year, primarily due to &#8220;soft&#8221; DIY demand in North America. Performance Coating Group sales were down 4.8% in the quarter. Paint Stores Group sales fared better, seeing 1.2% sales growth during the period, primarily driven by selling price increases. 
The company returned&nbsp;$552.1 million&nbsp;to shareholders in the first quarter in the form of dividends and repurchases. Sherwin-Williams ended the period with $199.8 million in cash and cash equivalents.
&#8220;In a demand environment that remained choppy as we anticipated, Sherwin-Williams continued to execute our strategy and delivered solid&nbsp;first quarter&nbsp;results driven by gross margin expansion and good cost control,&#8221; said Heidi Petz, chair, president and CEO of Sherwin-Williams.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45061797/us-stock-futures-edge-higher-tuesday-expert-warns-of-perfect-volatility-storm-with-major-earnings-and-economic-data-due-this-week">US Stock Futures Edge Higher Tuesday: Expert Warns Of &#8216;Perfect Volatility Storm&#8217; With Major Earnings And Economic Data Due This Week</a>
Guidance: Sherwin-Williams expects second-quarter revenue to be up or down in the low-single digit percentage range. The company guided for full-year 2025 net sales growth in the low-single digit percentage range. 
Sherwin-Williams also expects full-year adjusted earnings of $11.65 to $12.05 per share versus estimates of $11.90 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;We continue to expect demand softness to persist in several end markets well into the second half of the year. Regarding current tariffs, it&#8217;s important to remember that the largest portion of our revenue is in&nbsp;the United States, and the majority of our raw materials are sourced in the regions where we manufacture. In a macro-economic environment that remains turbulent, we are focused on being a source of stability and reliability for our customers, providing them with differentiated solutions that increase their productivity and profitability,&#8221; Petz said.
SHW Price Action: <a href="http://benzinga.com/quote/SHW">Sherwin-Williams shares</a> were up 5.46% at $350.33 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

Sherwin-Williams Reports Mixed Q1 Results In 'Choppy' Demand Environment

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">epidermolysis bullosa (RDEB)</a>.
RDEB is&nbsp;a severe, genetically inherited skin disorder characterized by blistering and skin fragility, often presenting at birth.
Zevaskyn is the only FDA-approved product to treat RDEB wounds <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061116/u-s-fda-approves-zevaskyn-prademagene-zamikeracel-the-first-and-only-cell-based-gene-therapy-for-p" rel="noreferrer noopener">with a single application</a>.
Zevaskyn consists of a patient&#8217;s skin cells (keratinocytes) genetically modified to produce functional Type VII collagen. Zevaskyn sheets are surgically applied to the patient&#8217;s wounded areas. In a single application, up to 12 credit card-sized sheets can be combined to cover large areas or applied to multiple distinct wounds, allowing for significant coverage of affected body areas.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
Zevaskyn is expected to be available beginning in the third quarter of 2025 through Zevaskyn Qualified Treatment Centers.
The FDA approval is based on the pivotal Phase 3 VIITAL study, which met its two co-primary efficacy endpoints, demonstrating statistically significant healing of 50% or more from baseline in large chronic RDEB wounds and pain reduction from baseline as assessed by the Wong-Baker FACES scale, as evaluated at six months after treatment.
Across 43 large and chronic wounds treated with a single application of Zevaskyn, 81% of wounds showed 50% or more healing (P&lt;0.0001) as evaluated at six months, compared to 16% in 43 matched control wounds treated with standard-of-care.
The most common adverse events were observed in fewer than 5% of patients, including procedural pain and itch.
The Phase 1/2a study of Zevaskyn, which involved 38 chronic wounds across seven patients, showed that a single surgical application of Zevaskyn was associated with long-term improvement at treated sites over a median follow-up of 6.9 years, ranging from 4 to 8 years.
Last April, the FDA issued a Complete Response Letter (CRL) in response to the company&#8217;s Biologics License Application (BLA) for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38380100/fda-rejects-approval-of-abeona-therapeutics-skin-disorder-treatment-shares-sink" rel="noreferrer noopener">pz-cel for RDEB</a>.&nbsp;
The FDA noted that certain additional information&nbsp;was needed&nbsp;to&nbsp;satisfy Chemistry Manufacturing and Controls (CMC) requirements.&nbsp;
Price Action: ABEO stock is up 2.34% at $5.46 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45079889/regeneron-pharmaceuticals-q1-earnings-falls-short-on-expectations-revises-2025-gross-margin-outlook" target="_blank" rel="noreferrer noopener">Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides</a></li>
</ul>
Photo via Shutterstock

Health Care

General

ABEO

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy

Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Sleep Number will report an earnings per share (EPS) of $-0.05. 
Investors in Sleep Number are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 41.89% drop in the share price the next day.
Here's a look at Sleep Number's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.23</td>
<td>-0.17</td>
<td>-0.37</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.14</td>
<td>-0.22</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-42.0%</td>
<td>4.0%</td>
<td>20.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953405_0.png" alt="eps graph" />
<h3>Sleep Number Share Price Analysis</h3>
Shares of Sleep Number were trading at $7.4 as of April 28. Over the last 52-week period, shares are down 43.34%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SNBR/earnings">To track all earnings releases for Sleep Number visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNBR

Earnings Outlook For Sleep Number

Oatly Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Oatly Group to report an earnings per share (EPS) of $-0.84.
The market awaits Oatly Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $1.60, leading to a 37.69% increase in the share price on the subsequent day.
Here's a look at Oatly Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.4</td>
<td>-1.2</td>
<td>-1.4</td>
<td>-1.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-3</td>
<td>-1.2</td>
<td>-1</td>
<td>-1.6</td>
</tr>
<tr>
<td>Price Change %</td>
<td>38.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953397_0.png" alt="eps graph" />
<h3>Tracking Oatly Group's Stock Performance</h3>
Shares of Oatly Group were trading at $10.0 as of April 28. Over the last 52-week period, shares are down 55.98%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OTLY/earnings">To track all earnings releases for Oatly Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OTLY

Oatly Group Earnings Preview

<ul>
<li>IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.</li>
<li>IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or heterogeneous Nectin-4 expression, as well as in models resistant to EV.</li>
<li>IPH4502 showed strong preclinical activity across multiple tumor types, including triple-negative breast cancer, head and neck, and esophageal cancers, supporting its potential for broad clinical application.</li>
</ul>
Innate Pharma SA (PARIS:<a class="ticker" href="https://www.benzinga.com/stock/IPH#PARIS">IPH</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

IPHA

PARIS:IPH

Innate Pharma Presents New Preclinical Data For IPH4502 AACR Annual Meeting 2025; IPH4502 Shows Strong Preclinical Activity Across Multiple Tumor Types

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Pulmonx will report an earnings per share (EPS) of $-0.40. 
Pulmonx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.12 in the last quarter, leading to a 32.23% increase in the share price on the following day.
Here's a look at Pulmonx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.45</td>
<td>-0.45</td>
<td>-0.42</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.36</td>
<td>-0.39</td>
<td>-0.36</td>
</tr>
<tr>
<td>Price Change %</td>
<td>32.0%</td>
<td>-8.0%</td>
<td>-6.0%</td>
<td>22.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953386_0.png" alt="eps graph" />
<h3>Market Performance of Pulmonx's Stock</h3>
Shares of Pulmonx were trading at $5.19 as of April 28. Over the last 52-week period, shares are down 31.09%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LUNG/earnings">To track all earnings releases for Pulmonx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LUNG

Pulmonx's Earnings Outlook

<ul>
<li>Preclinical data on AbCellera's PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies</li>
</ul>

Events

ABCL

AbCellera Presents Data For Preclinical Efficacy Of PSMA x CD3 T-Cell Engagers At AACR 2025

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Surmodics will report an earnings per share (EPS) of $-0.09. 
Investors in Surmodics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 4.06% drop in the share price on the subsequent day.
Here's a look at Surmodics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.29</td>
<td>-0.33</td>
<td>-0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.13</td>
<td>-0.27</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953377_0.png" alt="eps graph" />
<h3>Tracking Surmodics's Stock Performance</h3>
Shares of Surmodics were trading at $31.1 as of April 28. Over the last 52-week period, shares are down 7.53%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Insights on Surmodics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Surmodics.
With 1 analyst ratings, Surmodics has a consensus rating of Buy. The average one-year price target is $43.0, indicating a potential 38.26% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Treace Medical Concepts, with an average 1-year price target of $9.17, suggesting a potential 70.51% downside.</li>
<li>Analysts currently favor an Buy trajectory for ClearPoint Neuro, with an average 1-year price target of $25.0, suggesting a potential 19.61% downside.</li>
<li>Analysts currently favor an Buy trajectory for Delcath Systems, with an average 1-year price target of $24.0, suggesting a potential 22.83% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surmodics</td>
<td>Buy</td>
<td>-2.06%</td>
<td>$13.56M</td>
<td>-3.17%</td>
</tr>
<tr>
<td>Treace Medical Concepts</td>
<td>Neutral</td>
<td>10.44%</td>
<td>$55.48M</td>
<td>-0.46%</td>
</tr>
<tr>
<td>ClearPoint Neuro</td>
<td>Buy</td>
<td>14.11%</td>
<td>$4.76M</td>
<td>-19.81%</td>
</tr>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>2701.48%</td>
<td>$12.97M</td>
<td>-8.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Surmodics ranks at the bottom for Revenue Growth and Gross Profit, with negative values compared to peers. However, it ranks at the top for Return on Equity, showing a positive performance in this metric. The Consensus rating for Surmodics is in line with one peer and higher than the other two.
<h3>Delving into Surmodics's Background</h3>
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
<h3>Unraveling the Financial Story of Surmodics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Surmodics's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.06%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Surmodics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -12.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Surmodics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Surmodics's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SRDX/earnings">To track all earnings releases for Surmodics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SRDX

A Look at Surmodics's Upcoming Earnings Report

Standard Motor Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMP#NYSE">SMP</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Standard Motor Products to report an earnings per share (EPS) of $0.44.
The announcement from Standard Motor Products is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.03, leading to a 0.38% drop in the share price on the subsequent day.
Here's a look at Standard Motor Products's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>1.11</td>
<td>0.78</td>
<td>0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.47</td>
<td>1.28</td>
<td>0.98</td>
<td>0.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953361_0.png" alt="eps graph" />
<h3>Standard Motor Products Share Price Analysis</h3>
Shares of Standard Motor Products were trading at $23.94 as of April 28. Over the last 52-week period, shares are down 26.14%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SMP/earnings">To track all earnings releases for Standard Motor Products visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Standard Motor Products's Quarterly Earnings

MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that MiMedx Group will report an earnings per share (EPS) of $0.05. 
MiMedx Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.01, which was followed by a 1.62% increase in the share price the next day.
Here's a look at MiMedx Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.04</td>
<td>0.08</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.07</td>
<td>0.08</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>20.0%</td>
<td>-10.0%</td>
<td>19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953343_0.png" alt="eps graph" />
<h3>Tracking MiMedx Group's Stock Performance</h3>
Shares of MiMedx Group were trading at $6.83 as of April 28. Over the last 52-week period, shares are down 3.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on MiMedx Group</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MiMedx Group.
With 1 analyst ratings, MiMedx Group has a consensus rating of Outperform. The average one-year price target is $13.0, indicating a potential 90.34% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of CareDx, Vir Biotechnology and Iovance Biotherapeutics, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for CareDx, with an average 1-year price target of $30.33, suggesting a potential 344.07% upside.</li>
<li>Analysts currently favor an Buy trajectory for Vir Biotechnology, with an average 1-year price target of $58.2, suggesting a potential 752.12% upside.</li>
<li>Analysts currently favor an Buy trajectory for Iovance Biotherapeutics, with an average 1-year price target of $16.72, suggesting a potential 144.8% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for CareDx, Vir Biotechnology and Iovance Biotherapeutics, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MiMedx Group</td>
<td>Outperform</td>
<td>7.00%</td>
<td>$76.00M</td>
<td>3.98%</td>
</tr>
<tr>
<td>CareDx</td>
<td>Buy</td>
<td>32.04%</td>
<td>$58.40M</td>
<td>23.94%</td>
</tr>
<tr>
<td>Vir Biotechnology</td>
<td>Buy</td>
<td>17.45%</td>
<td>$10.59M</td>
<td>-8.75%</td>
</tr>
<tr>
<td>Iovance Biotherapeutics</td>
<td>Buy</td>
<td>15189.21%</td>
<td>$28.15M</td>
<td>-10.59%</td>
</tr>
</tbody>
</table>

Key Takeaway:
MiMedx Group ranks at the bottom for Revenue Growth and Gross Profit among its peers. However, it ranks at the top for Return on Equity.
<h3>Discovering MiMedx Group: A Closer Look</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>MiMedx Group: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, MiMedx Group showcased positive performance, achieving a revenue growth rate of 7.0% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: MiMedx Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.01% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): MiMedx Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.93% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: MiMedx Group's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MDXG/earnings">To track all earnings releases for MiMedx Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDXG

A Peek at MiMedx Group's Future Earnings

MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that MediaAlpha will report an earnings per share (EPS) of $0.35.
The announcement from MediaAlpha is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.36, leading to a 18.49% drop in the share price on the subsequent day.
Here's a look at MediaAlpha's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.12</td>
<td></td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.17</td>
<td>0.07</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-18.0%</td>
<td>-17.0%</td>
<td>13.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking MediaAlpha's Stock Performance</h3>
Shares of MediaAlpha were trading at $8.47 as of April 28. Over the last 52-week period, shares are down 58.78%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/MAX/earnings">To track all earnings releases for MediaAlpha visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: MediaAlpha's Earnings Outlook

Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Matthews International to report an earnings per share (EPS) of $0.38.
The market awaits Matthews International's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.08, leading to a 9.93% drop in the share price on the subsequent day.
Here's a look at Matthews International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.22</td>
<td>0.38</td>
<td>0.55</td>
<td>0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.14</td>
<td>0.55</td>
<td>0.56</td>
<td>0.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>21.0%</td>
<td>-5.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953327_0.png" alt="eps graph" />
<h3>Tracking Matthews International's Stock Performance</h3>
Shares of Matthews International were trading at $20.68 as of April 28. Over the last 52-week period, shares are down 19.43%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MATW/earnings">To track all earnings releases for Matthews International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MATW

Earnings Preview: Matthews International

OneSpaWorld Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate OneSpaWorld Holdings to report an earnings per share (EPS) of $0.21.
Anticipation surrounds OneSpaWorld Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS missed by $0.01 in the last quarter, leading to a 7.96% drop in the share price on the following day.
Here's a look at OneSpaWorld Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.21</td>
<td>0.23</td>
<td>0.2</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.20</td>
<td>0.26</td>
<td>0.2</td>
<td>0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953305_0.png" alt="eps graph" />
<h3>Tracking OneSpaWorld Holdings's Stock Performance</h3>
Shares of OneSpaWorld Holdings were trading at $17.24 as of April 28. Over the last 52-week period, shares are up 21.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OSW/earnings">To track all earnings releases for OneSpaWorld Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of OneSpaWorld Holdings's Earnings

CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that CTS will report an earnings per share (EPS) of $0.49. 
The market awaits CTS's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 1.89% increase in the share price the following trading session.
Here's a look at CTS's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.57</td>
<td>0.53</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.53</td>
<td>0.63</td>
<td>0.54</td>
<td>0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>2.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953298_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of CTS were trading at $39.8 as of April 28. Over the last 52-week period, shares are down 15.86%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/CTS/earnings">To track all earnings releases for CTS visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: CTS's Earnings Preview

Press Releases

Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference

Kenvue Announces Three New Appointments to Board of Directors

Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting

Kenvue Ribbon-Cutting Marks Official Opening of New Global Headquarters in Summit, New Jersey

Neutrogena® and John Cena Team Up for the Ultimate Disappearing Act in New Ultra Sheer ® Mineral Sunscreen Campaign

OGX® Haircare Introduces Shay Mitchell as First Global Brand Ambassador

Legal

KENVUE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Kenvue Inc. (NYSE: KVUE) and Encourages Long-Term KVUE Investors to Contact the Firm

Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations

Kenvue Declares Quarterly Cash Dividend

Kenvue to Announce First Quarter 2025 Results on May 8, 2025

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

Unilever

Upexi

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

Citigroup

Barclays

Redburn Atlantic

Evercore ISI Group

Canaccord Genuity

행동주의 투자자 스타보드 밸류 LP는 목요일(16일) 코보(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)의 지분 7.7%를 인수한 것응로 알려졌다. 운영 변경을 위한 잠재적인 타깃으로 부진한 반도체 제조업체를 겨냥한 것이다.
무슨 일 있었나: 월스트리트저널은 소식통을 <a href="https://www.wsj.com/finance/starboard-builds-big-stake-in-chip-maker-qorvo-7a18a71f" target="_blank" rel="noopener">인용해</a> 제프 스미스가 CEO가 이끄는 스타보드의 코보 지분 취득은 코보가 무선 주파수 칩 시장에서 점점 더 많은 도전에 직면하고 있는 가운데 나온 것이라고 보도했다.
노스캐롤라이나주 그린즈버러에 본사를 둔 코보의 주가는 지난 한 해 동안 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)과 스카이웍스 솔루션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) 같은 경쟁업체와 경쟁이 심화되면서 거의 28% 하락했다.
스타보드의 이번 투자는 2014년 RF 마이크로 디바이스(RF Micro Devices)와 합병하여 코보를 설립하기 전에 트라이퀸트 세미컨덕터(TriQuint Semiconductor)에 투자했던 스타보드가 친숙한 영역으로 복귀하는 것을 의미한다. 스타보드는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 마벨 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>)에 대한 이전 투자를 통해 반도체 부문에서 강력한 존재감을 유지해왔다.
코보의 최근 실적은 월가의 예상치를 하회한 후 주가가 폭락하면서 투자자들을 걱정스럽게 만들었다. 그랜트 브라운 CFO는 10월에 프리미엄 스마트폰에 대한 수요 약화를 언급하며 이러한 문제를 인정하고 수익성 개선을 위한 공장 통합 노력을 발표했다.
코보는 벤징가의 논평 요청에 즉시 응답하지 않았다.
왜 중요한가: 현재 약 70억 달러의 가치를 지닌 칩 제조사인 코보는 소비자들이 보급형 안드로이드 기기로 이동함에 따라 시장 지위를 유지하기 위해 고군분투하고 있다.
월가 애널리스트들은 <a href="https://www.benzinga.com/quote/QRVO/analyst-ratings" target="_blank" rel="noopener">컨센서스 목표주가</a>를 97.65달러로 유지하고 있지만, 최근 골드만삭스, 미즈호, 루프 캐피탈의 평가는 평균 77달러로 다소 완만한 기대치를 제시한다.
<img loading="lazy" decoding="async" class="alignnone size-medium" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17000713/Screenshot-2025-01-17-at-10.36.23%E2%80%AFAM-1024x376.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=2048" width="1024" height="376" />
스타보드의 코보 투자는 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), 켄뷰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), 라이엇 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>)에 대한 지분을 포함하는 <a href="https://www.benzinga.com/markets/equities/24/10/41419988/tylenol-listerine-maker-kenvue-under-activist-spotlight-with-starboard-value-stake-overhaul-ahea" target="_blank" rel="noopener">최근 일련의 행동주의적 포지션</a>에 추가되는 것이다.
주가 움직임: 코보는 목요일 시간외 거래에서 7.08% 급등한 78.80달러를 기록했다. <a href=""https://www.benzinga.com/pro/"">벤징가 프로 데이터에</a> 따르면 주가는 정규장에서 0.77% 하락한 73.59달러로 마감했으며 지난 1년 동안 27.43% 하락했다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%A7%90-%ED%81%AC%EB%A0%88%EC%9D%B4%EB%A8%B8-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%ED%8A%B8%EB%A0%88%EC%9D%B4%EB%94%A9-%ED%8C%A8%ED%84%B4%EC%97%90-%EC%9D%98%EB%AC%B8-%EC%A0%9C%EA%B8%B0/" target="_blank" rel="noopener">짐 크레이머, 엔비디아 트레이딩 패턴에 의문 제기</a>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 작성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

행동주의 투자자인 스타보드 밸류(Starboard Value)는 타이레놀(Tylenol) 및 리스테린(Listerine)과 같은 인기 소비자 제품을 생산하는 회사인 켄뷰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>)의 상당한 지분을 인수한 것으로 알려졌다.
무슨 일이 (What Happened): 스타보드 밸류는 작년에 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)에서 분사되어 시장 가치가 400억 달러가 넘는 켄뷰에서 변화를 추진하고 있다고 월스트리트 저널이 이 문제에 정통한 소식통들을 인용하여 <a href="https://www.wsj.com/business/deals/activist-starboard-value-takes-stake-in-tylenol-maker-kenvue-cc3175bb?mod=breakingnews" target="_blank" rel="noopener">보도</a>했다.
업계 최고의 소비자 브랜드들을 보유하고 있음에도 불구하고, 켄뷰의 주식은 1년 전 데뷔 이후 동종 업체들 및 더 넓은 시장에서 저조한 성과를 보였다.
켄뷰에 있어서 스타보드의 정확한 지분 규모과 이 회사에 대한 구체적인 아이디어는 알려져 있지 않다. 스타보드의 창립자이자 CEO인 제프 스미스(Jeff Smith)는 화요일 뉴욕에서 열리는 한 행동주의 투자 컨퍼런스에서 켄뷰에 대한 회사의 주장을 발표할 예정이다.
또한 보기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372090/anthony-scaramucci-tells-what-percentage-of-his-wealth-is-tied-up-in-bitcoin-i-havent-sold?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">앤서니 스카라무치가 비트코인에 묶인 자산 비율을 말하다: &#8216;나는 아무것도 팔지 않았다. 감사하다, 나무 두드리기!&#8217;</a>
켄뷰의 다른 브랜드들로는 아비노(Aveeno), 밴드에이드(Band-Aid), 지르텍(Zyrtec), 네오스포린(Neosporin) 및 뉴트로지나(Neutrogena) 등이 있다. 티보 몽곤(Thibaut Mongon) CEO가 이끄는 켄뷰는 2023년에 150억 달러 이상의 순매출을 기록했다.
켄뷰와 스타보드 밸류는 <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>의 논평 요청에 즉시 응답하지 않았다.
왜 이 일이 중요한가요 (Why It Matters): 켄뷰의 주가는 올해 S&amp;P 500 지수가 23% 상승한 것과 대조적으로 상대적으로 변동이 없었다. 켄뷰의 주요 경쟁사로는 애드빌(Advil)의 모회사인 헤일리온(Haleon), 펩토 비스몰(Pepto-Bismol)의 소유주인 프록터 앤드 갬블(Procter &amp; Gamble), 액스 데오드란트의 제조사인 유니레버(Unilever)가 있다.
스타보드의 최근 켄뷰 투자는 화이자의 약 10억 달러 규모의 지분 인수에 이어진 것으로, 여기서도 <a href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb" target="_blank" rel="noopener" data-google-interstitial="false">이 제약회사의 성과를 개선</a>하기 위해 다양한 변화를 모색하고 있다. 여기에는 현재 화이자 CEO인 알버트 불라(Albert Bourla)에 대한 지원을 약속한 전 화이자 임원인 이안 리드(Ian Read)와 프랭크 다멜리오(Frank D&#8217;Amelio)의 임명이 포함된다.
스타보드는 기술을 포함한 <a href="https://www.benzinga.com/markets/equities/24/07/39785537/tinder-parent-match-group-soars-nearly-9-in-after-hours-trading-as-activist-hedge-fund-starboard" target="_blank" rel="noopener" data-google-interstitial="false">다양한 분야에 적극적으로</a> 참여하는 것으로 알려져 있으며, 최근에는 세일즈포스(Salesforce), 오토데스크(Autodesk), 매치 그룹(Match Group)과 같은 회사들에서 노력을 기울이고 있다.
주가 움직임: 켄뷰의 주가는 금요일에 21.72달러로 마감했으며, 1.26% 상승하였다. 올해 초부터 현재까지 주가는 0.70% 상승했다.
다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/10/41409688/this-small-cap-nuclear-stock-is-up-over-100-in-a-month-will-it-keep-generating-momentum?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">이 소형 원자력 주식은 한 달 만에 100% 이상 상승했다. 계속해서 모멘텀을 생성할까?</a></li>
</ul>
이미지 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>에 의해 편집되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

8월에는 <a href="https://www.benzinga.com/news/earnings/24/08/40648231/wall-street-poised-for-strong-start-as-inflation-data-looms-strategist-says-brace-for-volatile-fall">주식 시장이</a> 7월 중순 정점 이후 겪은 손실을 만회했으며, 이는 실적과 양호한 데이터가 반등에 도움이 되었다. 8월을 뒤로 보내면서 시장 성과를 더욱 폭넓게 측정하는 S&amp;P 500 지수의 상승주와 하락주를 살펴보겠다.
세 가지 추세: 이번 달의 거래는 세 가지 추세로 특징지어질 수 있다. 주식은 8월까지 약세를 이어갔고, S&amp;P 500은 글로벌 주식 시장의 붕괴와 동시에 8월 5일에 바닥을 쳤다. 엔화 강세로 인한 엔캐리 트레이드의 청산은 위험 회피를 부추겨 일본 증시를 급락시켰고 그 반향은 다른 곳에서도 뚜렷이 드러났다.
S&amp;P 500 지수는 공교롭게도 월요일이었던 8월 5일 장중 4.3% 하락했다. 이 붕괴는 1987년 10월의 블랙 먼데이 붕괴와 구별하기 위해 즉시 블랙 먼데이 2.0으로 명명되었다. 일반적으로 VIX라고 불리는 CBOE 변동성 지수는 하락하기 전 장중 65.73으로 두 배 이상 상승했다.
긍정적인 점은 S&amp;P 500이 오늘의 저점을 마감했고 종가까지 3% 정도 하락했다는 것이다.
연방공개시장위원회(FOMC)가 9월 회의에서 금리 인하를 시작할 것이라는 기대감을 강화한 수많은 촉매제 덕분에 시장은 8월 22일까지 저점에서 꾸준히 회복세를 보였다.
강력하고 빠른 회복으로 인해 트레이더들은 방어적인 태도를 취하게 되었고, 그 이후로 시장은 횡보세로 전환되었다.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-524474" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325.png" sizes="(max-width: 819px) 100vw, 819px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325.png 819w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325-300x231.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/31133559/image-325-768x591.png 768w" alt="" width="819" height="630" /></figure>
출처: Yahoo Finance
8월 S&amp;P 500 지수는 2.28% 상승해 5,648.40으로 한 달을 마감했다. 이는 7월 16일 기록적인 종가인 5,667.20에서 조금 떨어진 수준이다.
참고: <a href="https://www.benzinga.com/money/best-growth-stocks">현재 최고의 성장주</a>
상승 주식들: 2023년 초부터 광범위한 시장 상승세를 주도해 온 매그니피센트 7개 종목 중 어느 종목도 상위 10개 종목에 포함되지 않았다. 이 목록에는 크라우드스트라이크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)와 포티넷(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>)라는 두 개의 사이버 보안 회사가 포함되어 있다. 크라우드스트라이크는 7월 19일 이후 글로벌 IT 중단으로 인한 하락세에서 반등하고 있었다.
포티넷은 실적 발표 후 강력한 반등으로 도움을 받았다.
두 개의 가정용 및 개인 관리 제품 회사들도 포함되었으며, 커피 체인 스타벅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)는 경영 변화로 주가가 상승했다.
8월의 상위 10개 상승주는 다음과 같다:
<ul>
<li>포장 식품 회사 켈라노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) (+38.62%) (주로 비상장 마즈(Mars)의 인수 소문과 그에 따른 거래 확인으로 인해 상승세를 보임)</li>
<li>포티넷 (+32.17%)</li>
<li>스타벅스 (+26.52%)</li>
<li>엑슨 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) (+21.65%); (실적 발표 후 8월 7일에 주가가 상승함)</li>
<li>크로락스 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) (+21.02%)</li>
<li>크라우드스트라이크(+19.54%)</li>
<li>켄뷰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) (+19.88%)</li>
<li>베스트 바이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) (+16.04%)</li>
<li>아치 캐피털 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NYSE">ACGL</a>) (+18.07%)</li>
<li>프로그레시브 손해보험사(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) (+17.78%)</li>
</ul>
하락 주식들: S&amp;P 500 지수에 편입된 후 꿈을 꾸었던 인공 지능 서버 제조업체 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)는 공매도 보고서와 회사의 10-K 보고서 제출 지연으로 인해 급락했다. 펀더멘털 리스크를 안고 있는 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)도 이번 달 최악의 실적을 거뒀다.
몇몇 소매업체들이 8월 S&amp;P 500 하락주 10개 목록에 포함되었다.
8월의 하락 주식 10개는 다음과 같다:
<ul>
<li>슈퍼 마이크로(-37.62%)</li>
<li>모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) (-35.08%)</li>
<li>달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) (-31.08%)</li>
<li>인텔(-27.86%)</li>
<li>월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) (-20.19%)</li>
<li>달러 트리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) (-19.02%)</li>
<li>찰스 리버 래보래토리즈 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) (-18.99%)</li>
<li>에어비앤비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) (-15.94)</li>
<li>배스 앤 바디 웍스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) (-15.80%)</li>
<li>엣시(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) (-15.43%)</li>
</ul>
실적 반응으로 인해 인텔 및 모더나를 포함한 일부 주식에서 나타난 약세가 촉발되어 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40139012/moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-c">연간 전망을</a> 낮췄다.
연방준비제도(연준)가 9월 금리 인하를 거의 결정함에 따라 이러한 하락세를 보인 주식 중 일부, 특히 소매관련 주식이 반등할 수 있다.
<a href="https://benzinga.grsm.io/register174">Benzinga Pro 데이터</a>에 따르면, S&amp;P 500 지수를 추적하는 상장지수펀드인 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 금요일 0.95% 상승한 563.68달러로 마감했다.
다음 기사 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40594093/economist-peter-schiff-warns-fed-may-be-committing-mistake-by-lowering-rates-in-sep">경제학자 피터 쉬프, 연준이 9월에 금리를 인하하면 실수할 수 있다고 경고</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

8월 S&P 500의 상위 상승주와 하락주: 매그 7종목은 빠지고, 사이버 보안 2종목 포함

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>쇼피파이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>)는 강력한 실적 보고서와 2024년 <a href="https://www.benzinga.com//node/40231028" target="_blank" rel="noreferrer noopener">3분기의 낙관적 전망</a>에 따라 주가가 41.15% 상승했다. 몇몇 분석가들은 주식의 <a href="https://www.benzinga.com//node/40268815" target="_blank" rel="noreferrer noopener">목표 주가</a>를 수정했다.</li>
<li>팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)의 주식은 예상보다 좋은 <a href="https://www.benzinga.com//node/40189435" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">실적을 발표하고 지침을 상향 조정</a>한 후 38.23% 급등했다. 또한 회사는 기밀 네트워크에 대한 향상된 분석 및 AI 서비스를 위해 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)와의 <a href="https://www.benzinga.com//node/40251032" target="_blank" rel="noreferrer noopener">파트너십</a>을 발표했다.</li>
<li>엑슨 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>)의 주식은 예상보다 나은 2분기 실적을 보고하고 FY24 <a href="https://www.benzinga.com//node/40201221" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매출 지침을 예상치보다 높인</a> 후 30.62% 급등했다. 많은 분석가들이 주식의 <a href="https://www.benzinga.com/quote/axon/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 높였다.</li>
<li>포티넷(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>)의 주식은 회사가 분기별 실적을 보고하고 예상치를 상회하는 지침을 발표한 후 29.95% 상승했다. 많은 분석가들은 주식의 <a href="https://www.benzinga.com/quote/ftnt/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 높였다.</li>
<li>트레이드 데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>)의 주가는 예상보다 나은 <a href="https://www.benzinga.com//node/40290308" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>과 강력한 3분기 매출 전망으로 28.63% 상승했다. 또한 몇몇 애널리스트들은 각각의 주식 <a href="https://www.benzinga.com/quote/ttd/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>나테라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>)의 주가는 예상보다 나은 2분기 재무 실적과 강력한 연간 매출 전망으로 지난 주 24.28% 상승했다. 몇몇 애널리스트들도 각자의 <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 상향 조정했다.</li>
<li>샤크닌자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>)의 주가는 최근 회사가 FY24 <a href="https://www.benzinga.com//node/40247206" target="_blank" rel="noreferrer noopener">2분기 재무 결과</a>를 보고한 후 23.21% 급등했다.</li>
<li>질로우 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>)의 주가는 예상보다 나은 <a href="https://www.benzinga.com//node/40237128" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 실적</a>에 힘입어 22.86% 상승했다.</li>
<li>아스펜 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>)의 주가는 회사가 4분기 <a href="https://www.benzinga.com//node/40226872" target="_blank" rel="noreferrer noopener">재무 실적</a>을 보고하고 강력한 지침을 발표한 후 20.99% 상승했다.</li>
<li>우버 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NASDAQ">UBER</a>)의 주가는 <a href="https://www.benzinga.com//node/40223273" target="_blank" rel="noreferrer noopener">예상보다 나은 분기</a> 실적을 발표한 뒤 20.73% 상승했다. 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com//node/40235721" target="_blank" rel="noreferrer noopener">목표 주가도</a> 상향 조정했다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40303623/warner-bros-airbnb-and-monster-beverage-are-among-top-10-large-cap-losers-last-week-aug-4-aug-10-a">워너 브라더스 및 에어비앤비는 지난주 최악의 성과를 보인 10개 대형주 중 일부 </a><a href="https://www.benzinga.com/news/large-cap/24/08/40303623/warner-bros-airbnb-and-monster-beverage-are-among-top-10-large-cap-losers-last-week-aug-4-aug-10-a">(8월 4일 &#8211; 8월 10일)</a></li>
</ul>
썸네일 사진 제공: Shuttershock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kenvue

뉴스

에 대한 최신 뉴스 Kenvue (NYSE:KVUE) 주식

금요일, 1월 17, 2025

월요일, 10월 21, 2024

토요일, 8월 31, 2024

일요일, 8월 11, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌